AF710B 是一种口服有效的变构 M1 毒蕈碱受体 (M1 muscarinic receptor) 和 σ1 受体 (σ1 receptor) 激动剂,可激活下游磷酸化 ERK1/2、磷酸化 CREB 信号通路,同时改善认知功能并减轻阿尔茨海默病的核心病理特征(包括 Aβ 沉积、Tau 过度磷酸化和神经炎症),可用于阿尔茨海默病的研究。
AF710B
产品编号: MS-Z31926 分子式: C20H27N3Os 分子量: 357.51
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

AF710B 是一种口服有效的变构 M1 毒蕈碱受体 (M1 muscarinic receptor) 和 σ1 受体 (σ1 receptor) 激动剂,可激活下游磷酸化 ERK1/2、磷酸化 CREB 信号通路,同时改善认知功能并减轻阿尔茨海默病的核心病理特征(包括 Aβ 沉积、Tau 过度磷酸化和神经炎症),可用于阿尔茨海默病的研究。

生物实验数据

生物活性 AF710B is an orally effective allosteric M1 muscarinic receptor and σ1 receptor agonist that activates downstream phosphorylated ERK1/2 and phosphorylated CREB signaling pathways, simultaneously improves cognitive function and attenuates the core pathological features of Alzheimer's disease, including Aβ deposition, Tau hyperphosphorylation, and neuroinflammation, and can be used for the study of Alzheimer's disease.
体外研究
(In Vitro)

AF710B (0.1-10 nM; 3 h) 可增强饥饿状态下 PC12M1 细胞中卡巴胆碱诱导的 ERK1/2 和 CREB 磷酸化,但不会单独引发这些反应。
AF710B (30 nM; 16 h) 可通过依赖功能性 M1 mAChRs 和完整 σ1R 表达的机制,挽救 PS1-KI 和 APP-KI 原代海马神经元培养物中的蘑菇状树突棘丢失,而对 nTg 培养物无影响。

Western Blot Analysis

Cell Line: rat pheochromocytoma PC12 cells stably transfected with rat M1 mAChR (PC12M1 cells)
Concentration: 0.1, 1 and 10 nM
Incubation Time: 3 h (pretreatment); 10 min (carbachol treatment)
Result: Did not increase phospho-ERK1/2 or phospho-CREB levels independently.
Significantly potentiated carbachol-induced phosphorylation of ERK1/2 and CREB at all tested concentrations.
体内研究
(In Vivo)

AF710B (1-30 µg/kg; p.o.; 单次给药) 可显著缓解 Trihexyphenidyl (MS-P81773) 诱导的大鼠认知损伤。
AF710B (10 µg/kg; i.p.; 每日一次共 2 个月) 可改善小鼠的认知功能,减少其 Aβ 病理改变、tau 蛋白过度磷酸化及神经炎症。

Animal Model: Wistar (male and female, 3 months old, 225-250 gr, trihexyphenidyl-induced cognitive impairment)
Dosage: 1 µg/kg; 3 µg/kg; 10 µg/kg; 30 µg/kg; 100 µg/kg
Administration: p.o.; single dose
Result: Significantly increased retention latency in trihexyphenidyl-treated rats compared to vehicle-treated trihexyphenidyl rats at 1, 3, 10, and 30 µg/kg doses.
Showed no significant effect at 100 µg/kg dose.
Demonstrated higher potency at 10 µg/kg dose than 100 µg/kg dose.
Lost anti-amnesic effect at 10 µg/kg dose when coadministered with σ1R antagonist NE-100.
Animal Model: 129/C57BL/6 (female, 10-12 months old, 3xTg-AD Alzheimer's disease model)
Dosage: 10 µg/kg
Administration: i.p.; daily; 2 months
Result: Improved cognitive function, as shown by decreased escape latency during Morris water maze training and increased time spent in the target quadrant during the probe trial.
Significantly reduced levels of soluble and insoluble Aβ40 and Aβ42, and decreased Thioflavin S-positive amyloid plaques.
Lowered BACE1 expression and levels of the β-secretase-derived APP C-terminal fragment C99, while leaving full-length APP and α-secretase (ADAM10, ADAM17) levels unchanged.
Reduced total phosphorylated tau (AT-100 epitope) and specific phospho-tau epitopes (AT180, AT270, PHF-1), while total tau levels remained unchanged.
Increased inhibitory Ser9 phosphorylation of GSK3β and reduced levels of the CDK5 activator p25.
Decreased neuroinflammation, as shown by reduced GFAP-positive astrocytes and Iba-1-positive microglia in the vicinity of Aβ plaques.

化学信息

分子量 357.51
分子式 C20H27N3Os

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础